Our approach is quite different from conventional CE. Through gathering data from many
hundreds of points and using proprietary signal processing algorithms, our technology is able
to produce better quality results than competing CE systems. deltaDOT patented multipoint
detection system (512 detection points, each sampling at around 20 cycles per second) tracks
the passage of biomolecule bands across the detection window. The proprietary software
derived from particle physics can determine which of the signals relate to the sample and
which do not, thus eliminating any extraneous effects and inaccuracies. deltaDOT's advanced
signal processing technology combined with multi-point detection produces high quality data,
i.e. sensitivity, resolution, quantification and repeatability.
Conventional Capillary Electrophoresis systems use single point detection. This means each
band of biomolecules is measured by just one detector. As a result biomolecules often need to
be 'labelled' with radiochemical, fluorescent, calorimetric, or luminescent compounds. Such CE
instruments cannot differentiate between extraneous interference, electrical noise, light source
fluctuations and other undesirable effects.
The core science behind LFII® originated in particle physics and is now being applied by
deltaDOT to biochemical analysis using Capillary Electrophoresis. The key to LFII® is the use
of a multi-pixel photo diode array (PDA) and the processing of the acquired signals. This large
data set is analysed by acquiring data from each band of biomolecules as it traverses each
pixel at a specific time point allowing for a distance-time correlation to be achieved. The
system measures the time it takes for any one band of biomolecules to traverse the detector
array and the software enables the molecular weight or charge-to-mass ratio to be calculated
from its velocity. This greatly improves signal-to-noise ratio offering molecular imaging which
outperforms single point detection systems. The deltaDOT system only works with the signals
that intersect the Vertex enabling LFII® to discriminate between system background noise -
the technique known as Vertexing.
to the HPCE-512
HPCE-512 technology selling into the biomedical, biopharmaceutical and analytics markets.
The company has sold nearly 30 systems so far. At its core is the proprietary Label Free
Intrinsic Imaging (LFII®) approach. LFII® has significant advantages over other approaches. It
has a wide spread of applications and customers in many sectors including biotech, academic,
industrial and government sectors. This technology addresses the PAGE, HPLC and to some
extent the Mass Spec markets.
24th January 2017 – deltaDOT Ltd. announces compliance with CFR 21 part 11 of USA’s
Food and Drug Administration. deltaDOT now offers an upgraded version of its control and
analysis software which has been designed to aid users of deltaDOT’s HPCE-512 Hig
Performance Capillary Electrophoresis instrument in achieving compliance with CFR 21 part
11.The upgrade package contains controls to help meet the stringent requirements of CFR
21 part 11 including the system access by authorised personel only, maintaining audit trails
of user actions, generating complete and protected data files and the application of
electronic signatures to data (...more)
20 Sep 2016 National Health Service Quality Control North West (QCNW) Liverpool labs
presented the data on monoclonal antibody stability trials based on deltaDOT’s Capillary
Electrophoresis (CE) technology and expertise. They state that CE technology is suitable for
monitoring the stability of monoclonal antibodies and can perform purity and charge analysis
with high resolution and repeatability. They conclude that CE can replace other techniques
commonly used for this analysis IEC and SDS PAGE (link to the poster).
3rd July 2016 Monoclonal Antibody Stability Trials using deltaDOT HPCE-512 technology
reported by Dr. Deepika Devanur. Now available in pdf slide format on our website (...more)
4th March 2016, FDA CFR21/11 Compliance - deltaDOT’s progress continues with the
implementation of the software quality system while the P3 controller system management
software and the P3EVA analysis package had their compliance completed previously
deltaDOT engineers are working with Optra systems of California (...more)
26th January 2016, National Health Service Quality Control North West (QCNW) Liverpool
Labs are to perform monoclonal antibody stability trials, utilising deltaDOT Ltd. technology
and expertise to aid the study.
4th February 2016 Webinar: Improve your Monoclonal Antibodies Analysis. Live webinar
on analysing mAbs from production to patient. Given jointly by Horiba Scientific and
deltaDOT Ltd. Presented by Dr. Deepika Devanur (...registration site)
14th December 2015, deltaDOT technology used to define product quality for ImmBio
Ltd. deltaDOT Ltd (London) are pleased to announce that its Label Free Intrinsic Imaging
(LFII®) technology has been used to help ImmBio (Cambridge UK) to submit an
Investigational Medicinal Product Dossier (IMPD) as part of a clinical trial application to The
Medicines and Healthcare products Regulatory AgencMHRA (...more)
24th November 2015, NW Labs are to market a kidney function test developed by
deltaDOT Ltd and the Royal Veterinary College. At the London Vet Show held at Olympia
on 19 and 20 Nov 2015 it was announced that NW Labs are now promoting deltaDOT’s
Glomerular filtration rate (GFR) assay for measuring kidney function in cats and dogs. NW
Labs will refer cases of suspected early stage renal disease for measurement by deltaDOT
with interpretation and advice on management by expert clinicians at the Royal Veterinary
College, London (...more)
12-14 March 2015, 2nd International Conference on Label-Free Technologies
Boston Marriott Cambridge, MA, USA. Dr. Stuart Hassard will be speaking on Label free
intrinsic imaging high performance capillary electrophoresis - a powerful tool in analytical
4th, 5th March 2015 Keeping pace - Analytics for tomorrow’s biopharmaceuticals
conference, Leeds, UK. Dr. Stuart Hassard will be speaking on Label free intrinsic imaging
high performance capillary electrophoresis trends throughout biopharmaceutical process
Monoclonal Antibody Stability Trials Using High Performance Capillary Electrophoresis. Dr.
Deepika Devanur’s presentation at the Proteins and Antibodies Congress 18tgh - 19th April
2016. This presentation demonstrates the use of the HPCE-512 Capillary Electrophoresis
platform to provide a complete characterisation of a mAb product using a single analytical tool.
The use of HPCE to characterise the mAbs Rituximab and Infliximab
Reliability and automation of deltaDOT Analytical instruments is suitable for unattended (e.g.
overnight) operation which can increase productivity. deltaDOT Label Free LFII® system’s
superior performance and sensitivity obviate the need for expensive (and often toxic) chemical
labels. Design ergonomics, user friendly interface and unsurpassed results in one compact
bench top instrument often resulting in reducing the laboratory costs and overheads.